Synapse

← Blood Cancer Discovery

Papers in Blood Cancer Discovery

Page 6 · newest first

  1. Genotoxicity associated with retroviral CAR transduction of ATM-deficient T cellsBlood Cancer Discovery · 2024
  2. Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin AxisBlood Cancer Discovery · 2024
  3. CAR T-cell Resistance to Oncogenic TransformationBlood Cancer Discovery · 2024
  4. The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell MalignancyBlood Cancer Discovery · 2024
  5. “Myeloid” Mutations in ALL Are Not Uncommon: Implications for Etiology and TherapiesBlood Cancer Discovery · 2024
  6. Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell LymphomaBlood Cancer Discovery · 2024
  7. Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed MyeloblastsBlood Cancer Discovery · 2024
  8. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple MyelomaBlood Cancer Discovery · 2024
  9. Abstract P39: CFT7455, a novel IKZF1/3 degrader enhances the anti-myeloma activity of monoclonal and bispecific antibodies by augmenting immune responsesBlood Cancer Discovery · 2024
  10. Abstract P34: Bayesian networks modeling identifies a reliance of TP53 mutant AML on NF kappa B signalingBlood Cancer Discovery · 2024
  11. Abstract P21: VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid LeukemiaBlood Cancer Discovery · 2024
  12. Abstract P16: CBFA2T3-GLIS2 fusion leads to a distinct DNA methylation enhancer landscape in pediatric acute myeloid leukemiaBlood Cancer Discovery · 2024
  13. Abstract P20: Anti-CD123 CAR NK cells and cam161533 Trispecific Killer Engager have synergistic activity against Acute Myeloid LeukemiaBlood Cancer Discovery · 2024
  14. Abstract P04: Role of glucocorticoid receptor in normal and malignant germinal center B cellsBlood Cancer Discovery · 2024
  15. Abstract P06: Characterization of the Immune Tumor Microenvironment in a Diverse Cohort of Patients with Multiple MyelomaBlood Cancer Discovery · 2024
  16. Abstract P01: Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP InhibitionBlood Cancer Discovery · 2024
  17. Abstract P03: Splicing factor mutations induce stress granule upregulation in myeloid malignanciesBlood Cancer Discovery · 2024
  18. Abstract P26: Altered RNA Export Sensitizes to Nuclear Export Inhibition in SF3B1 Mutant MDSBlood Cancer Discovery · 2024
  19. Abstract P24: GABARAP deficiency drives resistance to immunogenic chemotherapy in multiple myelomaBlood Cancer Discovery · 2024
  20. Abstract P22: PVR (CD155) epigenetic status mediates adoptive cell therapy and anti-TIGIT response in Multiple MyelomaBlood Cancer Discovery · 2024
  21. Abstract P14: Efficacy of FHD-286 monotherapy and combinations against Menin inhibitor sensitive and resistant AML cellsBlood Cancer Discovery · 2024
  22. Abstract P07: Identification of the unique preleukemic bone marrow niche in acute myeloid leukemiaBlood Cancer Discovery · 2024
  23. Abstract P13: Genetic and epigenetic characterization of B-cell chronic lymphocytic leukemia with IG::BCL3-translocation provides evidence for a distinct biological entityBlood Cancer Discovery · 2024
  24. Abstract P10: B-cell lymphoma CRISPR screens: NSD2 loss confers EZH2 inhibition resistance, while AEBP2 is a specific genetic dependencyBlood Cancer Discovery · 2024
  25. Abstract P05: Testing patterns and referrals for monoclonal protein detection at John Peter Smith hospitalBlood Cancer Discovery · 2024
  26. Abstract P11: ARID1A mutations shape memory B-cell dynamics and confer sensitivity to SWI/SNF remodeling complex inhibition in lymphomaBlood Cancer Discovery · 2024
  27. Abstract P15: Cross-species DNA methylation profiling of T and B cell populations in T-PLL and B-CLL compared to TCL1 transgenic mouse modelsBlood Cancer Discovery · 2024
  28. Abstract P23: RHOA inactivation subverts IFN-γ response and promotes antigen escape in CAR-T resistant diffuse large B-cell lymphomaBlood Cancer Discovery · 2024
  29. Abstract P09: Splicing and translation in chronic myeloid leukemia cells adapting to bone marrow microenvironment and chemotherapyBlood Cancer Discovery · 2024
  30. Abstract P08: 10x spatial transcriptomics of human AML core bone marrow biopsies reveals the complex remodeling of the non-hematopoietic stromal microenvironment post-treatmentBlood Cancer Discovery · 2024
  31. Abstract P02: Uncovering Tailored Therapies for Acute Myeloid Leukemia in Children with Down SyndromeBlood Cancer Discovery · 2024
  32. Abstract P40: Therapeutic anti-B-cell Receptor antibody, WBMP-4, modulates malignant B-cell signaling and induces apoptosisBlood Cancer Discovery · 2024
  33. Abstract P38: Expanding the repertoire of physiologically relevant AML models to support new target drug discovery, compound screening, and predicting patient responses in clinical trialsBlood Cancer Discovery · 2024
  34. Abstract P33: Leveraging probabilistic causal disease models to understand molecular pathways and target resistance mechanisms in Multiple Myeloma with the CREBBP and EP300 bromodomain inhibitor, pocenbrodibBlood Cancer Discovery · 2024
  35. Abstract P17: Epigenomic fingerprinting of limited primary immune cells using automated CUT&RUNBlood Cancer Discovery · 2024
  36. Abstract P18: Splicing polymorphism rs12459419 modulates antibody-bound internalization of CD33 isoformsBlood Cancer Discovery · 2024
  37. Abstract P30: Therapeutic activation of pre-B-cell receptor signaling in high-risk pediatric ALL: exploiting TCF3 and MYC-linked vulnerabilitiesBlood Cancer Discovery · 2024
  38. Abstract P35: High-grade B-cell lymphomas with 11q aberrations show a dark zone expression profile similar to Burkitt lymphoma but with additional extension towards intermediate germinal center B-cellsBlood Cancer Discovery · 2024
  39. Abstract P36: BIOLOGY IN ACUTE LYMPHOBLASTIC LEUKEMIA FROM DIAGNOSIS TO FOLLOW-UP: A STUDY OF 48CASESBlood Cancer Discovery · 2024
  40. Abstract P27: Proteogenomic and metabolomic analysis of acute myeloid leukemia reveals molecular and functional underpinnings of cellular and clinical phenotypesBlood Cancer Discovery · 2024
  41. Abstract P32: CAR-NK Specific Targeting of Clonal TCRVβ Chain to Treat T-cell Non-Hodgkin's LymphomaBlood Cancer Discovery · 2024
  42. Abstract P19: Mitohormetic Regulation in Multiple Myeloma: Exploiting Mitochondrial Stress Responses for Therapeutic GainBlood Cancer Discovery · 2024
  43. Abstract P31: Graph-Based Deep Learning for Predicting Synergy in Multi-Drug Treatments for LeukemiaBlood Cancer Discovery · 2024
  44. Abstract P29: Zotatifin, the eukaryotic translation initiation factor 4A (eIF4A) inhibitor, synergizes with Venetoclax to inhibit acute myeloid leukemia cell growthBlood Cancer Discovery · 2024
  45. Abstract P28: Immunoproteasome inhibitors for the treatment of ALLBlood Cancer Discovery · 2024
  46. Abstract P25: Identification of biological components and novel clinical subsets of NPM1-mutated AML using an integrated, multi-omics approachBlood Cancer Discovery · 2024
  47. Abstract P37: Decoding Cancer Dependency and Molecular Pathways of Long Noncoding RNAs with a Novel CRISPR-Cas13d PlatformBlood Cancer Discovery · 2024
  48. Highlighted research articlesBlood Cancer Discovery · 2024
  49. Spatial Mapping of Hematopoietic Clones in Human Bone MarrowBlood Cancer Discovery · 2024
  50. Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119Blood Cancer Discovery · 2024